Johnson & Johnson's Remicade, a blockbuster drug that treats autoimmune dis...
TORONTO/MONTREAL - Johnson & Johnson’s Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec’s public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows.
Remicade’s eroding market share underscores a gradual shift underway in Canada, where biosimilars have been slowly catching on with doctors and patients. The drug is under pressure elsewhere - in the third quarter, total global sales fell 17.6%. That left some 86.6% of the market to J&J, down from nearly 100%. About 3.7 million people are enrolled in the plan.
Janssen said it is proposing agreements with Canadian governments to “provide the cost savings being sought.”Louis Bessette, a rheumatologist and professor at Université Laval in Quebec, said doctors in Quebec have gained more experience with biosimilars, and the court ruling did not change his prescribing choices.
“This slow uptake undermines the potential value that biosimilars can offer and the savings they can bring to the health care system,” Pfizer said in a statement.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Rafa Nadal angered by 'bullsh**' marriage question after ATP Finals defeatRafa Nadal rarely loses his cool on the tennis court, but his patience was soundly tested after losing in his ATP Finals opener Monday.
Consulte Mais informação »
Behind Google’s ‘Project Nightingale’: A Health Data Gold Mine of 50 Million PatientsGoogle's effort to store millions of patients' health records includes an interface much like its flagship search engine. A name search could reveal everything from patients' medications to their body temperatures.
Consulte Mais informação »
Myanmar accused at UN court of genocide against RohingyaMyanmar has been accused of genocide at the U.N.’s highest court for its campaign against the country’s Rohingya Muslim minority. More than 700,000 Rohingya have fled to neighboring Bangladesh to escape what has been called an ethnic cleansing campaign.
Consulte Mais informação »
Scientists see echoes of tobacco industry tactics in plan to overhaul EPA's public health rulesThis concept of targeting the transparency of the scientific process 'first appeared in tobacco industry documents in the 90s,' Gretchen Goldman, the research director for the Center for Science and Democracy at the Union of Concerned Scientists, told Newsweek. 'It was never about transparency.'
Consulte Mais informação »
Supreme Court leans toward Trump plan to end DACA program for nearly 700K undocumented immigrantsThe Supreme Court appeared likely to side with the Trump administration in its effort to end the DACA program for 660,000 undocumented immigrants.
Consulte Mais informação »
China’s Drug Market Is Opening UpHeard on the Street: Beijing’s health-care reforms are giving global pharmaceutical companies better access to the world’s second-largest drug market
Consulte Mais informação »